Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I assume Jane Harness is the intermediary between IPIX and the sites testing Brilacidin. Do you agree?
There are different schools of thought about listing a current employer on LinkedIn. Not listing a current employer protects one from suspicion of being open to feelers.
Some employers monitor employees for updating and ‘sprucing’ up their profile as it can indicate a job search is underway. Nowadays the employers primary interest lies in retaining good employees.
I’m sure some don’t want to admit here they work so they don’t list it but I doubt it’s a fair general assumption.
Meet Jane Harness Senior Vice President, Clinical Sciences and Portfolio Management
Ms. Harness is Senior Vice President, Clinical Sciences and Portfolio Management, for Innovation Pharma. Ms. Harness has over 20 years in domestic and international clinical drug development experience. Before joining Innovation, she served as Vice President, Clinical Operations, at Revance Therapeutics. Prior, she was the Head of Clinical Sciences, Dermatology and ATI Translational Research, at Novartis Institutes for Biomedical Research. Across fifteen years at Pfizer, she held the following notable positions: Global Clinical Lead, Inflammation and Immunology; Early Clinical Lead, Dermatology; and Clinical Trial Head and Process Improvement Lead, Experimental Medicine. Ms. Harness received a BS and MPhil (Protein Biochemistry) degree from University of Leicester, and a MSc (Clinical Pharmacology) from University of Aberdeen.
http://www.ipharminc.com/senior-management
“I wonder when the few remaining bulls will finally realize that which is so obvious to so many?“
I wonder when the IPIX ownership approval board will disband.
“ Brilacidin isn’t the answer or solution.”
I made no mention of Brilacidin.
Pavlovian response?
Yesterday I heard part of an NPR segment on long Covid. The person interviewed has a medical background and was careless one time. She’s still living with long Covid and it sounds unpleasant.
She mentioned how the entire vascular system is subject to inflammation which can inhibit vasodilation. She described it as one complication after another seeming to randomly appear.
The message I got was the search for answers and solutions around Covid remains active.
“ to believe what you just said: "Leo has the most at stake! Leo has the most to gain!". ”
You are falsely attributing non-existing direct quotes to me. This is unethical on multiple levels
“ Just not sure Leo and "company" (sounds strange to say that, uh?") really care as long as they continue to squeeze the long green out of our hides.”
The IPIX share price anywhere in high single or mediocre double digits could produce generational wealth for Leo. The ‘lifestyle’ slant is a relatively short game.
Any comparison of Spencer Pharma’s criminal history to what IPIX has going on is ludicrous.
“ According to the complaint, Amyot and Spencer “disseminated false and misleading press releases claiming that it had received an unsolicited buyout offer from a Mideast company for $245 million when, in fact, the purported buyout offer was not real.” ”
https://www.biospace.com/article/court-orders-ceo-of-fake-spencer-pharma-to-pay-bilked-investors-7-million-/
No one is buying it.
This use of absolutes is symptomatic.
I don’t recall ever seeing as much nose cutting for the purpose of face spiting as I’ve seen with IPIX.
I’m underwater and will assume personal accountability rather than spend valuable time sacrificing my sense of dignity.
There’s also the fact that IPIX ain’t over.
Sound feasible. I was concerned about having missed a dilution announcement.
Speaking of taxes…I wonder if I could claim Norchi as a dependent. :o)
Friday price range was 0.0136 - 0.0462 with over a million volume and a close -47.5%.
Does anyone know what happened? Serious responses only, please.
In my mind IPIX is not chasing the indication of the week, month or year.
Indication specific researchers are pursuing Brilacidin for its potential.
“ or “marks” as he always likes to call them.”
Do the two of you speak frequently?
"Follow the money."
I encourage this as it is proper business for the leveler of allegations to bear the onus of substantiation.
Last week I thought I'd pick up a few more GBTC in my Vanguard Roth account. This is when I learned the as of earlier this year Vanguard no longer allows crypto or OTC buys because it is contrary to 'their philosophy'.
Vanguard went "Nanny".
Mr Shapira seems to know things about market penetration.
"Gil Shapira brings forward 26+ years of engineering and product development and management experience, with over 17 years in the surgical laser industry. Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability, with a 43% CAGR on its way to more than 1200 global installations and performing 50,000+ surgeries annually in over 30 countries. Previously, Gil led product development and marketing at OmniGuide, a successful high-growth laser-based medical device spin-off out of the Massachusetts Institute of Technology (MIT)."
“ All caps in all red letters, is about as childish as the statement that was made! ”
There’s few thing more sad than a neglected attention whore.
"Working on both Imacs and an Android phone.
Close your browser and re-open it?"
The iHub app for Apple mobile iOS for iPad is buggy. In September 2022 the app developer claims to have fixed a mailbox issue where attempting to open the mailbox trashes the app and necessitates a delete and reinstall. The issue persists today and ADVFN has not expressed interest in a fix.
I hold little hope for incorporating the 'Like' button feature into the app.
I watched the video and found it ironic that at the :25 mark the semi leaving the factory with what I assume is Megapack battery on board is powered by a diesel engine.
https://electrek.co/2022/10/26/tesla-unveils-megafactory-battery-production-ramps-up/
I can see the ‘Like’ button on my PC but not on my iPad. Is anyone else experiencing the same?
There is a concern about Russia using nuclear weapons. The federal government has purchased $290M of Nplate, which can be used for both adults and children, is aimed at reducing the uncontrolled bleeding often caused by radiation. Nordic country suppliers are facing depleting supplies of iodine pills due to stockpiling.
The Corona virus appears to have found a way to circumvent immunity. Biological warfare is certain to be on the list of things the DOD is concerned about.
It's my belief that if the government finds a broad range anti-bacterial/anti-viral easily administered long shelf life drug all the niceties of the FDA's monolithic slow grind to approval will be fast forwarded.
As an investor in IPIX the burning question is whether Brilacidin qualifies for a role in a proactive response.
I wasn’t implying BeaMed manufactured the laser. I’m interested in whether the 1.5mm probe diameter mentioned in the NCH release is the same diameter that BeaMed uses. And whether a match would be unique enough information to support the possibility of BeaMed involvement.
The numbers don't match.
About the companies you mentioned: "Visualase uses a 980-nm diode laser with up to 15-W continuous-wave output, whereas NeuroBlate uses a 1064-nm diode laser with up to 12-W pulse mode output. Visualase’s laser is delivered via a 1.65-mm-diameter plastic catheter and diffusing tip fiber. NeuroBlate’s laser is delivered via two probe options: a 3.3-mm-diameter SideFire directional laser probe or a 2.2- or 3.3-mm FullFire diffusing tip probe. Visualase’s tip is cooled by circulating water, and NeuroBlate’s tip is cooled by internalized gas2."
https://www.photonics.com/Articles/Laser_Therapy_Reaches_Hard-to-Treat_Epilepsy/a67454
The NHS article: "The laser requires just a 1.5mm-wide probe into the skull with the fibre optic laser at the tip of the probe reaching and destroying the epilepsy-causing brain tissue from the inside by heating it.”
https://www.england.nhs.uk/2022/10/nhs-launches-laser-beam-brain-surgery-to-treat-epilepsy/
I am convinced that I once read about BeaMed using a 1.5mm probe but have not been able to find and verify. Asking for help to verify the BeaMed probe diameter.
Arch presentation at SAWC:
https://content.equisolve.net/archtherapeutics/media/a6c54554777a18fd7c9d1fadccf84134.pdf
They seem to be nice posters though. :o)
Arch Therapeutics’ AC5® Advanced Wound System to be Presented with Honors at 2022 Symposium on Advanced Wound Care (SAWC) Fall
https://finance.yahoo.com/news/arch-therapeutics-ac5-advanced-wound-104500387.html
Arch had two poster presentations at last weekend’s Symposium on Advanced Wound Care (SAWC) fall conference in Las Vegas.
I'm curious whether the ARTH share price will be up, down, or unchanged this week.
I just noticed:
IPIX has 995 followers on iHub with 1,049 posts in past 30 days.
Tesla (TSLA) has 1,008 followers with 939 posts in the past 30 days.
Lots of eyes on little IPIX.
Anyone know what was going on with ARTH yesterday? Over a million volume and at one point the share price spiked to .054. The close was up 47.38%
"Also, shareholders get a say on executive comp every 3rd year."
There's a strong likelihood I will have taken my lumps and walked away before it's time to worry about future executive comp. When I'm done with a stock I don't linger.
Here's the link to Annual meeting. Voting results begin around the 16:00 mark.
The issue I was most concerned about: "2: An Amendment to Articles of Incorporation to Affect a Reverse Stock Split of our Issued and Outstanding and Authorized Common Stock". Approved.
https://east.virtualshareholdermeeting.com/vsm/web?pvskey=ARTH2022
“to knock out all the archived press releases that reference K is a new low for Ehrlich.”
Why is this upsetting? Do other pharmas not pull info for compounds they’ve decided not to pursue off their websites?
Arch annual meeting was today. Did anyone here attend? If so, anything worth sharing?
The thing that surprised me about moth balling K is the announcement follows President Biden’s recent “moon shot” comment about finding cures for cancer.
In this case “moon shot” is in reference to President Kennedy’s bold 1961 comment about putting men on the moon.
I wish I had worded my post differently. I would have been more emphatic in my concern that Arch may mail out a bunch of samples with the thought that this in itself is an effective marketing campaign.
I used Boost as an example that free samples can work but the follow up requires resources that I'm not sure Arch can provide.
I inadvertently missed today's happy hour but I did receive a reminder from another investor that Rosh Hashanah begins this weekend so we may looking at a couple quiet days.
Getting free product through the door is good. Follow up to encourage them to try the product is important. Feedback on performance, ease of use, etc is critical.
This may sound trite but is based on real life observation where samples of a product were dropped off at clinics and hospitals by sales reps without aggressive follow up. It turned out the staff was taking the nutritional product home to their families. Once the sales approach was restructured the product succeeded.
To lend credibility without going into a long story I will provide this. Novartis Medical Nutrition bought Boost from Meade Johnson and after a few years of solid marketing Boost was sold to Nestle for a handsome price.
Yes, Leo did a deal with Fox Chase for B against fungi in July 2020.
https://www.globenewswire.com/en/news-release/2020/07/22/2065754/0/en/Innovation-Pharmaceuticals-Grants-Licensing-Rights-to-Fox-Chase-Chemical-Diversity-Center-Inc-for-Antifungal-Technology.html
Thanks. A nice way to cap off the week.